Galmed Pharmaceuticals (GLMD) Competitors $2.96 -0.04 (-1.33%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends GLMD vs. APM, ABVC, BIOR, BCLI, EDSA, GTBP, CANF, EVOK, ADIL, and VCNXShould you be buying Galmed Pharmaceuticals stock or one of its competitors? The main competitors of Galmed Pharmaceuticals include Aptorum Group (APM), ABVC BioPharma (ABVC), Biora Therapeutics (BIOR), Brainstorm Cell Therapeutics (BCLI), Edesa Biotech (EDSA), GT Biopharma (GTBP), Can-Fite BioPharma (CANF), Evoke Pharma (EVOK), Adial Pharmaceuticals (ADIL), and Vaccinex (VCNX). These companies are all part of the "pharmaceutical products" industry. Galmed Pharmaceuticals vs. Aptorum Group ABVC BioPharma Biora Therapeutics Brainstorm Cell Therapeutics Edesa Biotech GT Biopharma Can-Fite BioPharma Evoke Pharma Adial Pharmaceuticals Vaccinex Galmed Pharmaceuticals (NASDAQ:GLMD) and Aptorum Group (NASDAQ:APM) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their community ranking, media sentiment, risk, institutional ownership, valuation, profitability, dividends, earnings and analyst recommendations. Do insiders & institutionals have more ownership in GLMD or APM? 76.1% of Galmed Pharmaceuticals shares are owned by institutional investors. Comparatively, 3.8% of Aptorum Group shares are owned by institutional investors. 19.8% of Galmed Pharmaceuticals shares are owned by insiders. Comparatively, 64.0% of Aptorum Group shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Which has stronger earnings & valuation, GLMD or APM? Aptorum Group has higher revenue and earnings than Galmed Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGalmed PharmaceuticalsN/AN/A-$6.91M-$16.66-0.18Aptorum Group$431.38K8.84-$2.83MN/AN/A Does the media favor GLMD or APM? In the previous week, Galmed Pharmaceuticals and Galmed Pharmaceuticals both had 1 articles in the media. Galmed Pharmaceuticals' average media sentiment score of 0.75 beat Aptorum Group's score of 0.00 indicating that Galmed Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Galmed Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aptorum Group 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Does the MarketBeat Community favor GLMD or APM? Galmed Pharmaceuticals received 401 more outperform votes than Aptorum Group when rated by MarketBeat users. However, 68.33% of users gave Aptorum Group an outperform vote while only 63.69% of users gave Galmed Pharmaceuticals an outperform vote. CompanyUnderperformOutperformGalmed PharmaceuticalsOutperform Votes44263.69% Underperform Votes25236.31% Aptorum GroupOutperform Votes4168.33% Underperform Votes1931.67% Is GLMD or APM more profitable? Aptorum Group's return on equity of 0.00% beat Galmed Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Galmed PharmaceuticalsN/A -28.75% -24.98% Aptorum Group N/A N/A N/A Which has more volatility and risk, GLMD or APM? Galmed Pharmaceuticals has a beta of 0.8, indicating that its stock price is 20% less volatile than the S&P 500. Comparatively, Aptorum Group has a beta of 1.46, indicating that its stock price is 46% more volatile than the S&P 500. SummaryAptorum Group beats Galmed Pharmaceuticals on 7 of the 10 factors compared between the two stocks. Ad DTIWhen it comes to NVDA… “acceleration cycles” are the keyExpert options trader Graham Lindman has been working on a new way to tap into Nvidia’s options… By simply isolating outsized “acceleration cycles” within Nvidia stock (most investors don’t even know it exists)... And thanks to many months and late nights working out the kinks of the systems… They have finally found a way to target these cycles on Nvidia over and over again.Use this link to see Nvidia Unchained right away! Get Galmed Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for GLMD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GLMD vs. The Competition Export to ExcelMetricGalmed PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.89M$6.45B$5.03B$8.81BDividend YieldN/A8.11%5.16%4.06%P/E Ratio-0.1810.78135.4117.82Price / SalesN/A243.751,160.9774.56Price / CashN/A22.1633.5332.53Price / Book0.095.474.674.68Net Income-$6.91M$153.61M$119.07M$226.08M7 Day Performance-4.52%-2.00%-1.83%-1.04%1 Month Performance-36.75%-7.46%-3.60%1.04%1 Year Performance-31.50%31.82%31.66%26.28% Galmed Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GLMDGalmed Pharmaceuticals1.3899 of 5 stars$2.96-1.3%N/A-42.6%$1.89MN/A-0.1820Upcoming EarningsAPMAptorum Group0.3476 of 5 stars$0.74+1.4%N/A-54.6%$3.81M$431,378.000.0030Gap UpABVCABVC BioPharma0.7598 of 5 stars$0.57+7.6%N/A-66.4%$7.37M$150,000.00-0.6130Gap UpBIORBiora Therapeutics2.591 of 5 stars$1.62-0.6%$23.00+1,319.8%-87.9%$7.33M$892,000.00-0.13120Analyst ForecastHigh Trading VolumeBCLIBrainstorm Cell Therapeutics4.4432 of 5 stars$1.26+0.8%$30.00+2,281.0%-53.4%$7.18MN/A-0.2640Analyst UpgradePositive NewsEDSAEdesa Biotech3.1439 of 5 stars$2.20+0.5%$21.00+854.5%-27.9%$7.15MN/A0.0020Gap UpGTBPGT Biopharma0.2078 of 5 stars$3.19+1.6%N/A-54.2%$7.11MN/A0.008CANFCan-Fite BioPharma1.8046 of 5 stars$1.97-3.0%$18.00+813.7%-1.7%$6.97M$667,000.00-1.108Analyst DowngradeNews CoverageEVOKEvoke Pharma0.05 of 5 stars$4.56-3.0%N/A-69.5%$6.79M$5.18M-0.414Analyst ForecastADILAdial Pharmaceuticals2.878 of 5 stars$1.02+1.0%$8.00+684.3%-50.5%$6.54MN/A0.0020VCNXVaccinex0.5923 of 5 stars$3.71+13.8%N/A-70.2%$6.42M$570,000.00-0.0740 Related Companies and Tools Related Companies APM Competitors ABVC Competitors BIOR Competitors BCLI Competitors EDSA Competitors GTBP Competitors CANF Competitors EVOK Competitors ADIL Competitors VCNX Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:GLMD) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Galmed Pharmaceuticals Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Galmed Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
